Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irbesartan + trandolapril
- Development stage
- Unknown
- Lead developer
- Ottawa Hospital Research Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Irbesartan + trandolapril is a combination therapy investigated by the Ottawa Hospital Research Institute for the treatment of diabetic nephropathy. It consists of irbesartan, an angiotensin receptor blocker (ARB), and trandolapril, an angiotensin-converting enzyme (ACE) inhibitor. This combination aims to provide a more complete blockade of the renin-angiotensin-aldosterone system (RAAS) than monotherapy. Trandolapril works by inhibiting the ACE enzyme, which prevents the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. Irbesartan works by selectively blocking the binding of angiotensin II to the AT1 receptor. In the context of diabetic nephropathy, this dual mechanism is intended to reduce intraglomerular pressure and proteinuria, thereby slowing the progression of renal damage.
- Other names
- irbesartan and trandolaprilACE inhibitor and ARB combinationirbesartan + trandolapril combination
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)ACE (Angiotensin Converting Enzyme)
Beyond the preview
Go deeper on irbesartan + trandolapril.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irbesartan + trandolapril.